Protective efficacy of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) adjuvated with recombinant IL-15 and IL-21 against experimental toxoplasmosis in mice

BMC Infectious Diseases

Xing-Quan Zhu²  Dong-Hui Zhou³  Hui-Qun Song³  Eskild Petersen¹  Si-Yang Huang³  Zhong-Yuan Li²  Jia Chen³ 

[1]Department of Infectious Diseases, Clinical Institute, and Institute of Medical Microbiology and Immunology, Faculty of Health Sciences, Aarhus University, Aarhus, Denmark

[2]College of Animal Science and Veterinary Medicine, Heilongjiang Bayi Agricultural University, Daqing, Heilongjiang Province 163319, PR China

[3]State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Parasitology of Gansu Province, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu Province 730046, PR China

关键词: Protective immunity;    DNA vaccine;    pVAX-IL-15-IL-21;    TgCDPK1;    Toxoplasmosis;    Toxoplasma gondii;   

Others  :  1125632
DOI  :  10.1186/1471-2334-14-487

 received in 2014-02-11, accepted in 2014-09-02,  发布年份 2014

【 摘 要 】

Background

Toxoplasma gondii can infect all warm-blooded animals including humans. Infection with T. gondii is probably the leading cause of posterior uveitis in humans and the most comment route of transmission is raw and undercooked meat from infected animals. T. gondii calcium-dependent protein kinase 1 (TgCDPK1) plays a critical role in direct parasite motility, host-cell invasion, and egress.

Methods

We constructed a DNA vaccine expressing TgCDPK1 inserted into eukaryotic expression vector pVAX I and evaluated the immune protection induced by pVAX-CDPK1 in Kunming mice. Mice immunized with pVAX-CDPK1 intramuscularly and/or with a plasmid encoding IL-15 and IL-21 (pVAX-IL-21-IL-15). The immune responses were analyzed including lymphoproliferative assay, cytokine, antibody measurements, lymphocyte surface markers by flow cytometry and protective efficacy were measured as survival and cysts numbers after challenge 1 to 2 months post vaccination.

Results

Immunization with pVAX-CDPK1 or pVAX-IL-21-IL-15 alone developed strong humoral responses and Th1 type cellular immune responses, and the significantly (P < 0.05) increase of both the percentages of CD4+ and CD8+ T cells compared with all the controls (blank control, PBS, and pVAX). Co-injection of pVAX-IL-21-IL-15 significantly increased humoral and cellular immune responses compared to the group of pVAX-CDPK1 or pVAX-IL-21-IL-15. Challenge experiments showed that co-administration of pVAX-IL-21-IL-15 and pVAX-CDPK1 significantly (P < 0.05) increased survival time (19.2 ± 5.1 days) compared with pVAX-CDPK1 (17.3 ± 4.3 days) or pVAX-IL-21-IL-15 (12.0 ± 2.0 days) alone, and pVAX-IL-21-IL-15 + pVAX-CDPK1 significantly reduced the number of brain cysts (72.7%) in contrast to pVAX-ROP13 (45.7%) or pVAX-IL-21-IL-15 alone (43.6%).

Conclusions

TgCDPK1 is identified to be a promising vaccine candidate for inducing a strong humoral and cellular response against T. gondii infection, and thus synergistic of mIL-21 and mIL-15 can induce non-specific immune responses, but also facilitate specific humoral as well as cellular immune responses elicited by DNA vaccine against acute and chronic T. gondii infection in mice.

【 授权许可】

   
2014 Chen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Chen J, Xu MJ, Zhou DH, Song HQ, Wang CR, Zhu XQ: Canine and feline parasitic zoonoses in China. Parasit Vectors 2012, 5:152. BioMed Central Full Text
• [2]Duan G, Tian YM, Li BF, Yang JF, Liu ZL, Yuan FZ, Zhu XQ, Zou FC: Seroprevalence of Toxoplasma gondii infection in pet dogs in Kunming, Southwest China. Parasit Vectors 2012, 5:118. BioMed Central Full Text
• [3]Miao Q, Wang X, She LN, Fan YT, Yuan FZ, Yang JF, Zhu XQ, Zou FC: Seroprevalence of Toxoplasma gondii in horses and donkeys in Yunnan Province, Southwestern China. Parasit Vectors 2013, 6:168. BioMed Central Full Text
• [4]Robert-Gangneux F, Dardé ML: Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev 2012, 25:264-296.
• [5]Elmore SA, Jones JL, Conrad PA, Patton S, Lindsayand DS, Dubey JP: Toxoplasma gondii: epidemiology, feline clinical aspects, and prevention. Trends Parasitol 2010, 26:190-196.
• [6]Weiss LM, Dubey JP: Toxoplasmosis: A history of clinical observations. Int J Parasitol 2009, 39:895-901.
• [7]Dubey JP: Toxoplasmosis in sheep–the last 20 years. Vet Parasitol 2009, 163:1-14.
• [8]Dubey JP, Lago EG, Gennari SM, Su C, Jones JL: Toxoplasmosis in humans and animals in Brazil: high prevalence, high burden of disease, and epidemiology. Parasitology 2012, 139:1375-1424.
• [9]Kijlstra A, Jongert E: Control of the risk of human toxoplasmosis transmitted by meat. Int J Parasitol 2008, 38:1359-1370.
• [10]Zhang NZ, Chen J, Wang M, Petersen E, Zhu XQ: Vaccines against Toxoplasma gondii: new developments and perspectives. Expert Rev Vaccine 2013, 12:1287-1299.
• [11]Innes EA: Vaccination against Toxoplasma gondii: an increasing priority for collaborative research? Expert Rev Vaccines 2010, 9:1117-1119.
• [12]Gurunathan S, Klinman D, Seder RA: DNA vaccines: immunology, application and optimization. Annu Rev Immunol 2000, 18:927-974.
• [13]Hoft DF, Eickhoff CS, Giddings OK, Vasconcelos JR, Rodrigues MM: Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic Trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming. J Immunol 2007, 179:6889-6900.
• [14]Cherif MS, Shuaibu MN, Kurosaki T, Helegbe GK, Kikuchi M, Yanagi T, Tsuboi T, Sasaki H, Hirayama K: Immudnogenicity of novel nanoparticle-coated MSP-1 C-terminus malaria DNA vaccine using different routes of administration. Vaccine 2011, 29:9038-9050.
• [15]McCoy JM, Whitehead L, van Dooren GG, Tonkin CJ: TgCDPK3 regulates calcium-dependent egress of Toxoplasma gondii from host cells. PLoS Pathog 2012, 8:1003066.
• [16]Billker O, Lourido S, Sibley LD: Calcium-dependent signaling and kinases in apicomlexan parasites. Cell Host Microbe 2009, 5:612-622.
• [17]Lourido S, Shuman J, Zhang C, Shokat KM, Hui R, Sibley LD: Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in Toxoplasma. Nature 2010, 465:359-362.
• [18]Cui FD, Asada H, Jin ML, Kishida T, Shin-Ya M, Nakaya T, Kita M, Ishii M, Iwai M, Okanoue T, Imanishi J, Mazda O: Cytokine genetic adjuvant facilitates prophylactic intravascular DNA vaccine against acute and latent herpes simplex virus infection in mice. Gene Ther 2005, 12:160-168.
• [19]Bolesta E, Kowalczyk A, Wierzbicki A, Eppolito C, Kaneko Y, Takiguchi M, Stamatatos L, Shrikant PA, Kozbor D: Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery. J Immunol 2006, 177:177-191.
• [20]Hryniewicz A, Price DA, Moniuszko M, Boasso A, Edghill-Spano Y, West SM, Venzon D, Vaccari M, Tsai WP, Tryniszewska E, Nacsa J, Villinger F, Ansari AA, Trindade CJ, Morre M, Brooks D, Arlen P, Brown HJ, Kitchen CM, Zack JA, Douek DC, Shearer GM, Lewis MG, Koup RA, Franchini G: Interleukin-15 but not interleukin-7 abrogates vaccine-induced decrease in virus level in simian immunodeficiency virus mac251-infected macaques. J Immunol 2007, 178:3492-3504.
• [21]Li ZY, Chen J, Petersen E, Zhou DH, Huang SY, Song HQ, Zhu XQ: Synergy of mIL-21 and mIL-15 in enhancing DNA vaccine efficacy against acute and chronic Toxoplasma gondii infection in mice. Vaccine 2014, 32:3058-3065.
• [22]Bounous DI, Campagnoli RP, Brown J: Comparison of MTT colorimetric assay and tritiated thymidine uptake for lymphocyte proliferation assays using chicken splenocytes. Avian Dis 1992, 36:1022-1027.
• [23]Chen J, Huang SY, Li ZY, Yuan ZG, Zhou DH, Petersen E, Zhang NZ, Zhu XQ: Protective immunity induced by a DNA vaccine expressing eIF4A of Toxoplasma gondii against acute toxoplasmosis in mice. Vaccine 2013, 31:1734-1739.
• [24]Yuan ZG, Ren D, Zhou DH, Zhang XX, Petersen E, Li XZ, Zhou Y, Yang GL, Zhu XQ: Evaluation of protective effect of pVAX-TgMIC13 plasmid against acute and chronic Toxoplasma gondii infection in a murine model. Vaccine 2013, 31:3135-3139.
• [25]Min J, Qu D, Li C, Song X, Zhao Q, Li XA, Yang Y, Liu Q, He S, Zhou H: Enhancement of protective immune responses induced by Toxoplasma gondii dense granule antigen 7 (GRA7) against toxoplamosis in mice using a prime-boost vaccination strategy. Vaccine 2012, 30:5631-5636.
• [26]Cui X, Lei T, Yang D, Hao P, Li B, Liu Q: Toxoplasma gondii immune mapped protein-1(TgIMP1) is a novel vaccine candidate against toxoplasmosis. Vaccine 2012, 30:2282-2287.
• [27]Denkers EY, Bzik DJ, Fox BA, Butcher BA: An inside job: hacking into Janus kinase/signal transducer and activator of transcription signaling cascades by the intracellular protozoan Toxoplasma gondii. Infect Immun 2012, 80:476-482.
• [28]Grover HS, Blanchard N, Gonzalez F, Chan S, Robey EA, Shastri N: The Toxoplasma gondii peptide AS15 elicits CD4 T cells that can control parasite burden. Infect Immun 2012, 80:3279-3288.
• [29]Correa D, Cañedo-Solares I, Ortiz-Alegría LB, Caballero-Ortega H, Rico-Torres CP: Congenital and acquired toxoplasmosis: diversity and role of antibodies in different compartments of the host. Parasite Immunol 2007, 29:651-660.
• [30]Dupont CD, Christian DA, Hunter CA: Immune response and immunopathology during toxoplasmosis. Semin Immunopathol 2012, 34:793-813.
• [31]Zhang NZ, Huang SY, Zhou DH, Chen J, Xu Y, Tian WP, Lu J, Zhu XQ: Protective immunity against Toxoplasma gondii induced by DNA immunization with the gene encoding a novel vaccine candidate: calcium-dependent protein kinase 3. BMC Infect Dis 2013, 13:512. BioMed Central Full Text
• [32]Munoz M, Liesenfeld O, Heimesaat MM: Immunology of Toxoplasma gondii. Immunol Rev 2011, 240:269-285.
• [33]Donnelly JJ, Wahren B, Liu MA: DNA vaccines: progress and challenges. J Immunol 2005, 175:633-639.
• [34]Yan HK, Yuan ZG, Petersen E, Zhang XX, Zhou DH, Liu Q, He Y, Lin RQ, Xu MJ, Chen XL, Zhong XL, Zhu XQ: Toxoplasma gondii: protective immunity against experimental toxoplasmosis induced by a DNA vaccine encoding the perforin-like protein 1. Exp Parasitol 2011, 128:38-43.
• [35]Wang PY, Yuan ZG, Petersen E, Li J, Zhang XX, Li XZ, Li HX, Lv ZC, Cheng T, Ren D, Yang GL, Lin RQ, Zhu XQ: Protective efficacy of a Toxoplasma gondii rhoptry protein 13 plasmid DNA vaccine in mice. Clin Vaccine Immunol 2012, 19:1916-1920.
• [36]Eickhoff CS, Vasconcelos JR, Sullivan NL, Blazevic A, Bruna-Romero O, Rodrigues MM, Hoft DF: Co-administration of a plasmid DNA encoding IL-15 improves long-term protection of a genetic vaccine against Trypanosoma cruzi. PLoS Negl Trop Dis 2011, 5:e983.